Legend Biotech CARVYKTI Milestones Contrast With Mixed Long Term Share Returns [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
Legend Biotech reported that more than 10,000 patients have now been treated with its CARVYKTI multiple myeloma therapy. The company announced an expansion of its Raritan facility, which it says is now the largest cell therapy manufacturing site in the US. These updates highlight a step up in both commercial usage and production capacity for CARVYKTI. For investors watching NasdaqGS:LEGN, these milestones arrive after a period of mixed share price performance. The stock last closed at $25.22, with a 34.9% gain over the past week and a 44.9% gain over the past 30 days, while the 1 year return stands at a 26.9% decline and the 3 year return at a 63.2% decline. This combination of recent strength and longer term weakness may draw attention to how CARVYKTI traction relates to the broader Legend Biotech story. With over 10,000 treated patients and a scaled up US manufacturing footprint, investors now have fresh information to assess how Legend Biotech is positioned in multiple mye
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech: Undervalued Leader In The CAR-T Race [Seeking Alpha]Seeking Alpha
- Legend Biotech (LEGN) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Why Legend Biotech Stock Crushed the Market on Monday [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Why Legend Biotech Stock Crushed the Market on Monday [Yahoo! Finance]Yahoo! Finance
- Is Legend Biotech (LEGN) One of the Overlooked Growth Stocks to Buy Now? [Yahoo! Finance]Yahoo! Finance
LEGN
Sec Filings
- 4/14/26 - Form 6-K
- 3/27/26 - Form 4
- 3/26/26 - Form 144
- LEGN's page on the SEC website